patent cliffs and the associated hole in revenue seems to be an ever present concern with big pharma. This angle is very compelling and very clear. If we don’t see something come out of this it could be considered commercially irresponsible from Amgen (based on what we know).
Ann: Bisantrene Highly Active in a Multiple Myeloma Mouse Model, page-12
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |